In order to obviate concerns about potential on-target/off-tumor toxicities, we have previously demonstrated that transient transfection of T cells with CSPG4-CARs using mRNA electroporation might be an effective and safe tool in cancer immunotherapy [41,42]. This evidence concerns the gene CSPG4 and cancer.